An open label signal detection study to evaluate the effects of cariprazine on cognitive functioning in patients with schizophrenia in need of adjustment of oral antipsychotic treatment

Status

Recruiting

Phases

Phase 4

Study type

Interventional

Source

EU CTIS

Registry ID

CTIS2024-518042-24-00

Acronym

CariCog

Enrollment

Registered

2024-10-29

Start date

2021-03-21

Completion date

Unknown

Last updated

2024-10-29

For informational purposes only — not medical advice. Sourced from public registries and may not reflect the latest updates. Terms

Conditions

schizophrenia

Brief summary

To investigate changes in the BACS and HFERST scores and in fMRI data from baseline to week 28

Detailed description

Longitudinal changes in the following measures: 1. PANSS 2. NSA-4 3. CGI 4. CDRS 5. SHRS/SMARTS 6. MARS 7. PSP 8. EQ-5D

Interventions

DRUGReagila 1.5 mg hard capsules

Eligibility

Sex/Gender

All

Age

18 Years to No maximum

Design outcomes

Primary

Measure	Time frame
To investigate changes in the BACS and HFERST scores and in fMRI data from baseline to week 28	—

Secondary

Measure	Time frame
Longitudinal changes in the following measures: 1. PANSS 2. NSA-4 3. CGI 4. CDRS 5. SHRS/SMARTS 6. MARS 7. PSP 8. EQ-5D	—

Countries

Austria

Outcome results

None listed

Source: EU CTIS · Data processed: Feb 4, 2026